Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Today’s study comes to us from the medical school at the University of Groningen in the Netherlands. It involves tracking the ...

A June 2025 study in Molecular Neurodegeneration assessed this topic and concluded that “up to 45% of dementia risk can be ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

The drama playing out over the late actor’s assets offers valuable lessons for anyone leaving an estate – large or small – to ...

"We discovered that bacteria all around us are using amyloids as a molecular suit of armor," said senior author Aaron Whiteley, assistant professor in the Department of Biochemistry.

Researchers have found a way to rejuvenate the glycocalyx, the “sugar shield” that bolsters the blood-brain barrier. Exciting ...

Walking and other lifestyle habits may slow cognitive decline in APOE ε4 carriers — possibly offering greater benefits than ...

The gunman accused of killing four people in New York City suspected he had chronic traumatic encephalopathy, or CTE — a ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...